Sandra Ekstedt has joined Oxcia as Senior Scientist, a very welcome reinforcement as Sandra has a strong background in inflammation, immunology and airway disease with a PhD and over 10 years of work in the field. Sandra will primarily work with OXC-201, Oxcias exciting project for Idiopathic pulmonary fibrosis (IPF), but will also be of great value for Oxcias other projects with promising potential in this area. Sandra comes most recently from Karolinska Institute (KI) and will in her role work very closely with KI, progressing the knowledge and further development of OXC-201.
New peer-reviewed article in Biomolecules, enforces the cancer cell selective killing of OXC-101. In a recently published article, Oxcia and its collaborators at Karolinska institute, shows that OXC-101 is extra efficacious in cancer cells overexpressing c-Myc (Hendriksson et al, Biomolecules… Continue reading New article enforces the cancer cell selective killing of OXC-101
Oxcia’s CEO Ulrika Warpman Berglund will attend the DDR Inhibitors Summit in Boston January 24-26th and present a poster describing the unique dual mechanism of action of OXC-101 and its potent and well tolerated anti-cancer effects. DDR is short for… Continue reading Oxcia attends DDR Inhibitors Summit in Boston
Tredje kvartalet (juli-september 2022) Rörelseresultatet uppgick till -10 927 043 (-3 573 590) SEK. Periodens resultat uppgick till -10 927 043 (-3 578 876) SEK. Kassaflödet från den löpande verksamheten uppgick till -4 612 924 (-2 749 079) SEK. Resultat per aktie före utspädning uppgick till -0,51… Continue reading Oxcia AB publicerar sin delårsrapport för tredje kvartalet 2022